ACADIA Pharmaceuticals is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. The company’s pipeline of product includes pimavanserin, which is in phase 3 development as a potential first-in-class treatment for Parkinson’s disease psychosis. ACAD also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan Inc., and two preclinical programs directed at Parkinson’s disease and other neurological disorders. For more information visit the company’s Web site at www.acadia-pharm.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: